NCT00459641View on ClinicalTrials.gov

Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 31, 2012

Primary Completion Date

June 30, 2014

Study Completion Date

July 31, 2019

Conditions
Bone Cysts
Interventions
DRUG

I-040302

doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34

OTHER

Standard of Care

Bone marrow aspirate or steroids

Sponsors
All Listed Sponsors
lead

Kuros Biosurgery AG

INDUSTRY

NCT00459641 - Safety and Tolerability of I-040302 in Children and Young Adults With Solitary Bone Cysts | Biotech Hunter | Biotech Hunter